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CD8+ T cells have long been considered crucial in 
the immune response against tumors. However, in the last 
decade a subpopulation of exhausted CD8+ T cells has 
been described which exhibit a dysfunctional phenotype 
and contribute to poor immune control of tumors and 
chronic viral infections. These findings led to the design 
of immunotherapies consisting in antibodies that block 
inhibitory receptors expressed by exhausted T cells in 
order to reinvigorate their effector function (known as 
“immune checkpoint blockade therapies”). This approach 
caused a great impact in clinics since an unprecedented 
number of treated cancer patients were able to recover 
the anti-tumor response mediated by CD8+ T cells [1]. 
Nevertheless, the durability of this enhancement is 
currently unknown, which raises the need to find new 
biomarkers to monitor the immune response against 
tumors. Moreover, these results also motivate the search 
for new immune checkpoints expressed by CD8+ T cells 
to design new immunotherapeutic approaches.
Many studies have highlighted the role of the 
ecto-enzyme CD39 in regulating immunity during 
chronic inflammatory diseases. This surface-expressed 
molecule is involved in the conversion of pro-
inflammatory extracellular ATP to adenosine, a very potent 
immunosuppressive factor. CD39 can be expressed by a 
variety of cells, but in the tumor microenvironment it 
has been mostly attributed to Foxp3+ regulatory T cells 
[2]. However, a few years ago Parodi et al. described 
the presence of CD8+ T cells expressing CD39 in tumor 
biopsies of patients with different types of cancer [3].
In the recently published article “CD39 expression 
defines cell exhaustion in tumor-infiltrating CD8+ T 
cells” in Cancer Research we showed that CD39 is 
expressed by a subset of CD8+ T cells which exhibit 
an impairment in effector cytokines production and 
high expression of inhibitory receptors, all features of 
exhausted T cells [4]. These CD39+CD8+ T cells were 
present in all three murine cancer experimental models 
used (melanoma, mammary carcinoma and fibrosarcoma) 
and in primary tumors and metastatic lymph nodes from 
breast cancer patients. In contrast, they were absent or 
poorly represented in non-metastatic lymphoid organs 
and peripheral blood. Notably, the frequency of a subset 
of tumor-infiltrating CD8+ T cells with high expression 
of the ecto-enzyme (CD39high) increased with tumor 
growth in mice, indicating that the continued exposure to 
the tumor microenvironment would be responsible for the 
generation of these cells. The findings highlight the value 
of CD39 as a maker for exhausted CD8+ T cells in cancer. 
These results also propose that exhausted T cells are not 
merely inert cells which have lost their effector functions 
since they could also acquire a regulatory phenotype that 
favors tumor progression. A high capacity to hydrolyze 
extracellular ATP by tumor-infiltrating exhausted CD8+ T 
cells further supports this hypothesis.
In addition, we observed that more immunogenic 
tumors induce a higher frequency of CD39highCD8+ T 
cells. This was observed by comparing tumor-infiltrating 
CD8+ T cells from mice bearing B16F10 and B16F10-
OVA tumors. The latter promote a more robust CD8+ T 
cell response, but at the same time a higher induction of 
the ecto-enzyme. Similar observations have been made 
in human cancers where highly immunogenic tumors 
promote the expression of inhibitory receptors and 
accumulation of exhausted T cells. It is in this type of 
tumors where checkpoint blockade therapies show better 
results (Figure 1). 
All the conclusions from this work are consistent 
with observations made by other groups who described the 
presence of CD39+CD8+ T cells in different pathological 
scenarios. Gupta et al. observed in peripheral blood 
from patients with chronic viral infections that CD8+ T 
cells that are specific for HIV or HCV antigens showed 
higher expression of CD39 than CD8+ T cells specific for 
other viruses that cause acute infections [5]. They also 
observed that these cells showed high expression of PD-1 
and exhibited a transcriptional signature consistent with 
exhaustion. A posterior work by other group showed that 
an elevated frequency of CD39+CD8+ T cells in patients 
co-infected with HIV and M. tuberculosis correlated with 
early mortality, despite anti-retroviral treatment initiation 
[6]. In another context, Bai et al. found an increase in the 
frequency of CD39+CD8+ T cells in peripheral blood 
and lamina propria from patients with Crohn disease, 
compared to healthy donors. They hypothesized that these 
cells could be harmful for patients due to their sustained 
production of IFNγ, a cytokine involved in the chronic 
inflammation of the disease [7]. Collectively, all these 
studies show that CD39+CD8+ T cells may represent a 
pathogenic cell subset in chronic inflammatory diseases, 
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which could be monitored for prognosis and patient´s 
follow up. 
Noble et al. studied CD39+CD8+ T cells in a quite 
different scenario. They described the induction of these 
cells in mice that were administered with tolerogenic 
doses of ovalbumin [8], and proposed that they were 
involved in the modulation of the response against the 
foreign antigens. The work suggests a different angle of 
study of CD39+CD8+ T cells, in which their induction 
could be beneficial in the context of autoimmune diseases 
and allergies.
All these works together are in contrast with the 
anti-viral and anti-tumor functions that are usually 
attributed to CD8+ T cells. Particularly, our results point 
CD39 as a molecule that could be used to address the 
presence of exhausted T cells in cancer patients and follow 
their functionality during and after treatments. Even more, 
CD39 may emerge as a new immune checkpoint, which 
could be targeted to restore CD8+ T cell tumor immunity.
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Figure 1: The tumor microenvironment elicits a subset of functionally exhausted CD8+ T cells that express the 
modulatory ectoenzyme CD39.
